tbuckley/cabot-search huggingface dataset:
Magnetic Resonance guided adaptive Radiotherapy (MRgRT) for localised prostate cancer: The first result from a prospective international registry for the evidence-based Introduction of MRgRT
Authors: F.R. Teunissen, T. Willigenburg, A.C. Tree, W.A. Hall, S.L. Choi, A. Choudhury, J.P. Christodouleas, J.C.J. De Boer, E.N. De Groot-Van Breugel, L.G.W. Kerkmeijer, F.J. Pos, D. Vesprini, H.M. Verkooijen, J.R.N. Van Der Voort Van Zyp
Journal: European Urology (2021)
ESWL for lower calyx stones. Results, complications and analysis of the factors associated with treatment success. Development of a predictive model
Authors: M. Mata Alcaraz, I. Laso García, A. Artiles Medina, G. Duque Ruiz, M. Hevia Palacios, F. Arias Fúnez, F.J. Burgos Revilla
Journal: European Urology (2021)
Macrophage and neutrophil death programs differentially confer resistance to tuberculosis
Authors: Michael Dominic Stutz, Cody Charles Allison, Samar Ojaimi, Simon Peter Preston, Marcel Doerflinger, Philip Arandjelovic, Lachlan Whitehead, Stefanie M. Bader, Daniel Batey, Marie-Liesse Asselin-Labat, Marco J. Herold, Andreas Strasser, Nicholas P. West, Marc Pellegrini
Journal: Immunity (2021)
The role of nuclear export in primary high-risk prostate cancer: A genomic analysis identifies XPO1 as potential therapeutic agent in high risk prostate cancer
Authors: L. Moris, T. Van Den Broeck, C. Buerki, E. Davicioni, W. Everaerts, F. Handle, C. Helsen, M. Jacquemyn, Y. Landesman, S. Soenen, D. Daelemans, S. Joniau, F. Claessens
Journal: European Urology (2021)
Renal trauma: Risk factors associated with nephrectomy; proposal of a 3-point score to aid surgical decision making
Authors: R. Pallares-Mendez, D.E. Cervantes-Miranda, E.S. Castillo-Godinez, C. De La Cruz-De La Cruz, M.A. Aguilar-Méndez, A. Gutiérrez-González, F. Mendoza-Castillo, H. Mata-Torres, M. Ochoa-Arvizo, F. Montelongo-Rodríguez, K.L. Hernández-Aranda, J.A. Cota-Agüero
Journal: European Urology (2021)
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial
Authors: Stephen A. Harrison, Peter J. Ruane, Bradley L. Freilich, Guy Neff, Rashmee Patil, Cynthia A. Behling, Chen Hu, Erica Fong, Brittany de Temple, Erik J. Tillman, Timothy P. Rolph, Andrew Cheng, Kitty Yale
Journal: Nature Medicine (2021)
On the Genetic and Environmental Relationship Between Suicide Attempt and Death by Suicide
Authors: Alexis C. Edwards, Henrik Ohlsson, Eve Mościcki, Casey Crump, Jan Sundquist, Paul Lichtenstein, Kenneth S. Kendler, Kristina Sundquist
Journal: American Journal of Psychiatry (2021)

The authors examined the extent to which the genetic and environmental etiology of suicide attempt and suicide death is shared or unique.The authors used Swedish national registry data for a large cohort of twins, full siblings, and half siblings (N=1,314,990) born between 1960 and 1990 and followed through 2015. They conducted twin-family modeling of suicide attempt and suicide death to estimate heritability for each outcome, along with genetic and environmental correlations between them. They further assessed the relationship between suicide attempt by young people compared with adults.In bivariate models, suicide attempt and death were moderately heritable among both women (attempt: additive genetic variance component [A]=0.52, 95% CI=0.44, 0.56; death: A=0.45, 95% CI=0.39, 0.59) and men (attempt: A=0.41, 95% CI=0.38, 0.49; death: A=0.44, 95% CI=0.43, 0.44). The outcomes were substantially, but incompletely, genetically correlated (women: rA=0.67, 95% CI=0.55, 0.67; men: rA=0.74, 95% CI=0.63, 0.87). Environmental correlations were weaker (women: rE=0.36, 95% CI=0.29, 0.45; men: rE=0.21, 95% CI=0.19, 0.27). Heritability of suicide attempt was stronger among people ages 10-24 (A=0.55-0.62) than among those age 25 and older (A=0.36-0.38), and the genetic correlation between attempt during youth and during adulthood was stronger for women (rA=0.79, 95% CI=0.72, 0.79) than for men (rA=0.39, 95% CI=0.26, 0.47).The genetic and environmental etiologies of suicide attempt and death are partially overlapping, exhibit modest sex differences, and shift across the life course. These differences must be considered when developing prevention efforts and risk prediction algorithms. Where feasible, suicide attempt and death should be considered separately rather than collapsed, including in the context of gene identification efforts.
The importance of neurophysiological study and computed tomography-guided perineural injection in the characterization of pudendal neuropathy
Authors: A. Artiles Medina, L. López-Fando Lavalle, M. Ruiz Hernández, E. Alcaraz Zomeño, G. Martín Palomeque, I. Gallego Rivera, Á. Sánchez González, M. Mata Alcaraz, M.Á. Jiménez Cidre, F.J. Burgos Revilla
Journal: European Urology (2021)
Multi-responsive nanotheranostics with enhanced tumor penetration and oxygen self-producing capacities for multimodal synergistic cancer therapy
Authors: Shuangquan Gou, Nanxi Chen, Xiaoai Wu, Menghang Zu, Shixiong Yi, Binwu Ying, Fangyin Dai, Bowen Ke, Bo Xiao
Journal: Acta Pharmaceutica Sinica B (2021)

Incorporation of multiple functions into one nanoplatform can improve cancer diagnostic efficacy and enhance anti-cancer outcomes. Here, we constructed doxorubicin (DOX)-loaded silk fibroin-based nanoparticles (NPs) with surface functionalization by photosensitizer (N770). The obtained nanotheranostics (N770-DOX@NPs) had desirable particle size (157 nm) and negative surface charge (-25 mV). These NPs presented excellent oxygen-generating capacity and responded to a quadruple of stimuli (acidic solution, reactive oxygen species, glutathione, and hyperthermia). Surface functionalization of DOX@NPs with N770 could endow them with active internalization by cancerous cell lines, but not by normal cells. Furthermore, the intracellular NPs were found to be preferentially retained in mitochondria, which were also efficient for near-infrared (NIR) fluorescence imaging, photothermal imaging, and photoacoustic imaging. Meanwhile, DOX could spontaneously accumulate in the nucleus. Importantly, a mouse test group treated with N770-DOX@NPs plus NIR irradiation achieved the best tumor retardation effect among all treatment groups based on tumor-bearing mouse models and a patient-derived xenograft model, demonstrating the unprecedented therapeutic effects of trimodal imaging-guided mitochondrial phototherapy (photothermal therapy and photodynamic therapy) and chemotherapy. Therefore, the present study brings new insight into the exploitation of an easy-to-use, versatile, and robust nanoplatform for programmable targeting, imaging, and applying synergistic therapy to tumors.
Abstract 2361: The functional roles of miRNA-193a-3p in colorectal cancer
Authors: Sakura Hiraide, Masanobu Takahashi, Yuya Yoshida, Keigo Komine, Chikashi Ishioka
Journal: Cancer Research (2021)

Abstract Background: Patients with BRAF-mutated colorectal cancer (CRC) have a poor prognosis despite recent therapeutic advances such as combination therapy with BRAF, MEK, and EGFR inhibitors. Aim: Our aim was to clarify the functions of the microRNAs (miRNAs) involved in oncogenesis and sensitivity to BRAF inhibitors and MEK inhibitors in BRAF-mutated CRC. Methods and Results: To identify miRNAs that sensitize a BRAF inhibitor dabrafenib (DAB) and a MEK inhibitor trametinib (TRA), we screened 240 miRNAs in BRAF-mutated CRC cell line RKO. Among the screened miRNAs, we tried to elucidate the novel functional roles of miR-193a-3p in CRC cell lines. We found that miR-193a-3p overexpression inhibited cell proliferation in CRC cell lines. The protein array analysis revealed that protein phosphorylation levels were altered by miR-193a-3p overexpression in various pathways such as cell-cycle-related pathways and PI3K-AKT pathways. The enhanced cytotoxicity by miR-193a-3p in addition to DAB and TRA was validated in multiple BRAF-mutated cell lines. Furthermore, the enhanced cytotoxicity by miR-193a-3p in addition to DAB and TRA was shown to be through inhibiting reactivation of MAPK signaling. This enhanced cytotoxicity by miR-193a-3p was even observed under treatment of DAB, TRA, and an anti-EGFR antibody. Conclusions: Our study shows that miR-193a-3p regulates multiple proteins involved in oncogenesis, and proposes that the combination therapy of miR-193a-3p and BRAF/MEK inhibitors could be a promising treatment strategy in BRAF-mutated CRC. Citation Format: Sakura Hiraide, Masanobu Takahashi, Yuya Yoshida, Keigo Komine, Chikashi Ishioka. The functional roles of miRNA-193a-3p in colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2361.
Abstract 3121: Characterization of nab-paclitaxel resistant and gemcitabine resistant BxPC3 and MIA PaCa-2 pancreatic cancer cells
Authors: Danielle M. Arias, John Collins, Pawan Noel, Daniel D. Von Hoff, Haiyong Han
Journal: Cancer Research (2021)

Abstract The gemcitabine (Gem) and nab-paclitaxel (Nab-p) combination is currently the FDA approved standard of care for patients with Stage IV metastatic pancreatic cancer. The response rate of the Gem and Nab-p regimen ranges from 23% to 46%, with many patients eventually becoming refractory. The specific aim of this research project is to determine which genes and pathways differ in Gem resistant (GemR) or Nab-p resistant (Nab-pR) MIA PaCa2 (MP2) and BxPC3 cells when compared with their parental cell lines. Cell proliferation assays were carried out to confirm resistance of the cell lines. The IC50 values of gemcitabine in the Gem resistant BxPC3 (BxPC3-GemR) and MP2 (MP2-GemR) are 26 and 64 fold higher than those in the corresponding parental cell lines, respectively. The IC50 values of nab-paclitaxel in the Nab-p resistant BxPC3 (BxPC3-Nab-pR) and MP2 (MP2-Nab-pR) are 13 and 140 fold higher than those in the corresponding parental cell lines, respectively. RNA sequencing (RNA-seq) was then performed to compare the gene expression profiles of the parental and resistant cell lines. Gene set enrichment analysis (GSEA) revealed that differentially expressed genes between Gem resistant and parental BxPC3 cell lines are often enriched in pathways associated with endoplasmic reticulum (ER) stress response (e.g. ATF-6 and XBP1) whereas in MP2 cells, The AMPK signaling pathway (e.g. PRKAB1, and PRKAG1) seemed to be activated in Gem resistant cells. NFkB signaling pathway (e.g. RIPK2 and NFKB2) was elevated in both Nab-p resistant BxPC3 and MP2 cell lines compared to their corresponding parental cell lines. Genes from these pathways were selected for further validation of their differential expression using RT-PCR. ATF6 which is a stress sensor and transducer in the ER is upregulated in BxPC3-GemR. PRKAB1 and PRKAG1 which regulate AMPK activity are upregulated in MP2-GemR. RIPK2 and NFKB1 are both up in the Nab-p resistant cell lines. Results from this study could provide insights on how to devise new therapeutic regimens to overcome resistance to gemcitabine and nab-paclitaxel. Citation Format: Danielle M. Arias, John Collins, Pawan Noel, Daniel D. Von Hoff, Haiyong Han. Characterization of nab-paclitaxel resistant and gemcitabine resistant BxPC3 and MIA PaCa-2 pancreatic cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 3121.
Abstract 967: Phosphodiesterase 4D depletion enhances anti-tumor effects of tyrosine kinase inhibitor in renal cell carcinoma involving CRAF-ERK pathway
Authors: Minghua Cao, Amrandra K. Ajay, Martin Gasser, Li-LI Hsiao, Ana Maria Waaga-Gasser
Journal: Cancer Research (2021)

Abstract Clear cell renal cell carcinoma (ccRCC) is the most lethal form of kidney cancer. Small molecule Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors are widely used but are not curative and various resistant mechanisms have been described. Previous studies have indicated a crosstalk between the cAMP pathway and the MAPK pathway, and the elevation of cAMP levels by Phosphodiesterase 4 (PDE4) inhibition can result in growth arrest and/or cell death. In this study we focused on the effects of PDE4 in ccRCC. We showed for the first time that PDE4D is the dominant subtype of PDE4 in kidney. PDE4D depletion in ccRCC, Caki-1 cells, using CRISPR Knock Out (KO) enhanced sensitivity of Tyrosine Kinase Inhibitor (TKI), sorafenib and increased cytotoxicity. We also showed synergistic effects of PDE4 inhibitor, roflumilast and sorafenib, in increasing cytotoxicity of ccRCC in the absence of PDE4D. Our results further demonstrated that PDE4D deficiency increased intracellular cAMP levels and resulted in downregulation of MAPK but not PI3K/AKT signaling in a CRAF dependent manners. In conclusion, we provide a preclinical rationale for dual PDE4/VEGFR inhibition in patients with ccRCC. While the MAPK signaling pathway is activated in ccRCC, dual inhibitions may improve the anti-tumor effects in patients with proven CRAF signaling activation. Citation Format: Minghua Cao, Amrandra K. Ajay, Martin Gasser, Li-LI Hsiao, Ana Maria Waaga-Gasser. Phosphodiesterase 4D depletion enhances anti-tumor effects of tyrosine kinase inhibitor in renal cell carcinoma involving CRAF-ERK pathway [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 967.
Rapid Serial Immunoprofiling of the Tumor Immune Microenvironment by Fine Needle Sampling
Authors: Juhyun Oh, Jonathan C.T. Carlson, Christian Landeros, Hakho Lee, Scott Ferguson, William C. Faquin, John R. Clark, Mikael J. Pittet, Sara I. Pai, Ralph Weissleder
Journal: Clinical Cancer Research (2021)

There is increasing effort to discover and integrate predictive and/or prognostic biomarkers into treatment algorithms. While tissue-based methods can reveal tumor-immune cell compositions at a single time point, we propose that single-cell sampling via fine needle aspiration (FNA) can facilitate serial assessment of the tumor immune microenvironment (TME) with a favorable risk-benefit profile.
Selumetinib for optic pathway glioma: Seeing through the fog, (not yet) the end of the tunnel?
Authors: Vijay Ramaswamy, Ute Bartels
Journal: Neuro-Oncology (2021)

See the article by Fangusaro et al. pp. 1777–1788 Low-grade gliomas in children whenever not amenable to a resection represent one of the most challenging entities in pediatric neuro-oncology.1 Although transformation to higher-grade tumors is rare, current therapies consist of multiple rounds of conventional chemotherapy with a goal to preserve function, in anticipation of potential senescence where many children still proceed to radiotherapy. Unfortunately, many children suffer from lifelong sequelae of their tumor or treatment, and as such new treatment approaches are being explored.2 A major biological distinction between adult and pediatric low-grade gliomas (pLGG) is a near-uniform enrichment for activating lesions in BRAF (either fusion or mutation) with subsequent activation of the Ras/MAPK pathway, where MEK inhibition has been suggested as a rationale therapy.1 First results on selumetinib for recurrent/refractory pLGG from the Pediatric Brain Tumor Consortium (PBTC) have shown very promising activity.3,4...
Significant reduction of urinary incontinence episodes in patients with neurogenic detrusor overactivity treated with abobotulinumtoxinA (aboBoNT-A): Pooled results of the phase III CONTENT program
Authors: P. Denys, A.G. Giannantoni, C. Thompson, M. Volteau, C. Vilain, M. Kennelly
Journal: European Urology (2021)
Abstract 14184: Identification of Small Molecules That Ameliorate Morphological Abnormalities of Hypertrophic Cardiomyopathy in Human IPS Cell-Derived Cardiomyocytes
Authors: Kohei Deguchi, Shigeru Kondo, Ayaka Sakoda, Kenichi Imahashi, Kenji Miki, Tomoyuki Nishimoto, Tsukasa Sugo, Yoshinori Yoshida
Journal: Circulation (2019)

Introduction: Hypertrophic cardiomyopathy (HCM) is mainly associated with mutations in sarcomere protein genes, such as MYH7. However, the molecular mechanisms of the HCM phenotype, such as cardiac...
A new risk calculator to predict changes in IPSS score and risk of AUR / BPH-related surgery in BPH patients with moderate-severe symptoms at risk of disease progression receiving placebo, dutasteride, tamsulosin, or combination therapy
Authors: S. Gravas, J.M. Palacios, D. Thompson, F. Concas, P.J. Kamola, C.G. Roehrborn, M. Oelke, M. Kattan, M.A. Averbeck, M. Manyak, Z. Lulic
Journal: European Urology (2021)
Abstract 1457: Discovery of biomarkers assocaited with treatment responses to sorafenib and transarterial chemoembolisation (TACE) in Chinese hepatocellular carcinoma patients
Authors: Zhiqiang Wu, Xiaoyu Zhou, Shengzhou Wang, Jinhuai Li, Jun Liu, Wenbo Guo
Journal: Cancer Research (2021)

Abstract Background: Liver cancer is one of the most deadly tumors. Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancers. Sorafenib, a multi-target kinase inhibitor, is one the main systemic therapy drug of HCC. It increased the median overall survival time from 7.9 mo to 10.7 mo for patients with advanced stage HCC. However, about 60% of HCC patients done't respond well to sorafenib, and most of them develop progression in below 6 mo. Similarly, TACE is also an effective treatment of HCC but only with partial response rate. Therefore, finding new strategies to screen the best matched patients is key to improve the efficacy of sorafenib and TACE treatment. Methods: We evaluated the efficacy of sorafenib starting with 98 HCC patients but only 73 patients completed the study because 24 dropped out due to death (n=2), drug violation (n=4), adverse reactions (n=3), and failure of outcome evaluation (n=15). Forty-five patients were treated by TACE. We divided the patients to a progressive disease (PD) group (46.6%, 34 patients) and a Non-PD group (53.4%, including 2 with partial response and 37 with stable disease) based on their CT and MRI evaluations. At the same time, we performed Whole-exome sequencing (WES) on the tumor samples and patient-matched blood samples. Results: We found the PD group, comparing with the Non-PD group, had a higher proportion of patients with MSI (P = 0.028) and mutations in WNT/ß-catenin signaling and chromatin modification pathways, as well as cytoband deletions at 21q11, 1p21.1, 8q24.3, 11p11.12, 5p15.33, and 17q25.3. On contrast, cytoband amplifications at 12p13, 21q22.3, and 8q21 only appeared in the Non-PD group. We also observed a prominent decrease in the PD group COSMIC mutational signature 10 which is believed to associate with POLE mutation. We found MUC16 and FLG2 genes were related to a better survival time. Mutation of NANOGNB, and cytoband deletions at 3q11.2, 4q13.2,11q11,11q22.2 and 17q25.3 were related to a shorter survival time. (p&amp;lt;0.05 for all above except otherwise specified). Conclusions: We found several genes and chromosome variation were associated with sorafenib efficacy and overall survival in HCC patients. These findings indicated that mutations and chromosomal fragment deletions can lead to sorafenib resistance. Mutations of MUC16 and FLG2 may be potential drug targets in HCC. Citation Format: Zhiqiang Wu, Xiaoyu Zhou, Shengzhou Wang, Jinhuai Li, Jun Liu, Wenbo Guo. Discovery of biomarkers assocaited with treatment responses to sorafenib and transarterial chemoembolisation (TACE) in Chinese hepatocellular carcinoma patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1457.
A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
Authors: Peihong Wang, Xinhua Xiao, Yuyin Zhang, Baoyuan Zhang, Donghe Li, Mingzhu Liu, Xi Xie, Chenxuan Liu, Ping Liu, Ruibao Ren
Journal: Journal of Hematology & Oncology (2021)

FLT3 mutations are the most frequently identified genetic alterations in acute myeloid leukemia (AML) and are associated with poor prognosis. Multiple FLT3 inhibitors are in various stages of clinical evaluation. However, resistance to FLT3 inhibitors resulting from acquired point mutations in tyrosine kinase domain (TKD) have limited the sustained efficacy of treatments, and a "gatekeeper" mutation (F691L) is resistant to most available FLT3 inhibitors. Thus, new FLT3 inhibitors against both FLT3 internal tandem duplication (FLT3-ITD) and FLT3-TKD mutations (including F691L) are urgently sought. Herein, we identified KX2-391 as a dual FLT3 and tubulin inhibitor and investigated its efficacy and mechanisms in overcoming drug-resistant FLT3-ITD-TKD mutations in AML. KX2-391 exhibited potent growth inhibitory and apoptosis promoting effects on diverse AML cell lines harboring FLT3-ITD mutations and AC220-resistant mutations at the D835 and F691 residues in TKD and inhibited FLT3 phosphorylation and its downstream signaling targets. Orally administered KX2-391 significantly prolonged the survival of a murine leukemia model induced by FLT3-ITD-F691L. KX2-391 also significantly inhibited the growth of 4 primary AML cells expressing FLT3-ITD and 2 primary AML cells expressing FLT3-ITD-D835Y. Our preclinical data highlight KX2-391 as a promising FLT3 inhibitor for the treatment of AML patients harboring FLT3 mutations, especially refractory/relapsed patients with F691L and other FLT3-TKD mutations.
SETD2 Loss of Function Is a Recurrent Event in Advanced-Phase Chronic Myeloid Leukemia
Authors: Manuela Mancini, Sara De Santis, Cecilia Monaldi, Luana Bavaro, Margherita Martelli, Fausto Castagnetti, Gabriele Gugliotta, Gianantonio Rosti, Alessandra Iurlo, Elisabetta Abruzzese, Marzia Salvucci, Patrizia Pregno, Antonella Gozzini, Monica Crugnola, Francesco Albano, Massimiliano Bonifacio, Elisabetta Calistri, Mario Tiribelli, Gianni Binotto, Annalisa Imovilli, Elena Trabacchi, Sara Galimberti, Claudia Baratè, Elena Tenti, Michele Baccarani, Michele Cavo, Giovanni Martinelli, Simona Soverini
Journal: Blood (2017)
Estrogen receptor‐low breast cancer: Biology chaos and treatment paradox
Authors: Ke‐Da Yu, Yu‐Wen Cai, Song‐Yang Wu, Ruo‐Hong Shui, Zhi‐Ming Shao
Journal: Cancer Communications (2021)

Hormone receptor testing mainly serves the purpose of guiding treatment choices for breast cancer patients. Patients with estrogen receptor (ER)-positive breast cancers show significant response to endocrine therapy. However, the methods to define ER status and eligibility for treatment remain controversial. Despite recent guidelines considering staining ≥1% of tumor nuclei by immunohistology as ER-positive, it has raised concerns on the benefit of endocrine therapy for tumors with ER 1%-10% expression, termed "ER-low positive". This subgroup accounts for 3% to 9% of all patients and is likely to have unique molecular features, and therefore distinct therapeutic response to endocrine therapy compared with ER-high positive tumors. The latest guidelines did not provide detailed descriptions for those patients, resulting in inconsistent treatment strategies. Consequently, we aimed to resolve this dilemma comprehensively. This review discusses molecular traits and recent ER-low positive breast cancer innovations, highlighting molecular-targeted treatment rather than traditional unified endocrine therapy for future basic and clinical research.
External validation of the VHL alliance guidelines for VHL genetic testing in patients diagnosed with renal cell carcionoma
Authors: A. Larcher, I. Rowe, G. Fallara, M. Romani, C. Doglioni, R. Lucianò, G. Casari, P. Carerra, M.G. Patricelli, A. Falini, S. Calloni, F. De Cobelli, G. Guazzarotti, P. Mortini, J. Capitanio, F. Bandello, R. Lattanzio, M. Falconi, S. Partelli, A. Necchi, D. Raggi, F. Montorsi, U. Capitanio, A. Salonia
Journal: European Urology (2021)